Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
The main study purpose is to demonstrate the non-inferiority of T4032 compared to Lumigan® 0.01% in terms of efficacy.
Inclusion Criteria:
Exclusion Criteria:
Monrovia, California 91016-1938, United States
Newport Beach, California 92663-3642, United States
Petaluma, California 94954-2355, United States
Redlands, California 92373-3125, United States
Palm Beach Gardens, Florida 33418-3701, United States
Indianapolis, Indiana 46202-5209, United States
Portland, Oregon 97210-3049, United States
Philadelphia, Pennsylvania 19104-2640, United States
Nashville, Tennessee 37232-0025, United States
San Antonio, Texas 78229-3539, United States